Pidotimod vs HBD-3
Head-to-head comparison of Pidotimod (3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid) and HBD-3 (Human Beta-Defensin 3) — benefits, dosing, side effects, research data, and where to buy.
| Property | Pidotimod | HBD-3 |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | 3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid | Human Beta-Defensin 3 |
| Molecular Weight | 244.27 Da | 5158 Da |
| Half-Life | 3-4 h | Minutes to hours; protease-sensitive |
| Amino Acids | 2 | 45 |
| Typical Dose | 400-800 mg/day | Research use only; no approved human dose |
| Route | Oral | Topical / Intranasal / Research parenteral |
| Purity | ≥98% | ≥98% |
| Studies Count | 200 | 380 |
| Research Status | Clinical | Pre-clinical |
Pidotimod Benefits
- ✓oral-immune-support
- ✓respiratory-infection-adjunct
- ✓innate-immunity
- ✓adaptive-immunity-support
HBD-3 Benefits
- ✓strong antimicrobial activity
- ✓skin and mucosal defense
- ✓innate immune signaling modulation
- ✓wound-healing support
Pidotimod Dosing
400 mg PO BID|typically 15-30 days|repeated seasonal cycles in studies
HBD-3 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Pidotimod Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠rash
HBD-3 Side Effects
- ⚠cell toxicity at high concentrations
- ⚠rapid proteolysis
- ⚠inflammatory activation in some contexts
Research Overview
Pidotimod
Pidotimod has human data in recurrent infections, especially where immune stimulation or reduced infection frequency is the target. Published work commonly reports improvements in phagocyte function, mucosal defense, and fewer respiratory infection episodes.
HBD-3
Human beta-defensin 3 has been examined in numerous in vitro and animal studies for antimicrobial and immunomodulatory activity. Research suggests it can help defend barrier tissues while influencing cytokine networks, chemotaxis, and epithelial repair.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.